Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT)—Relationship to Newly Identified Mitochondrial Pyruvate Carrier Proteins
Thiazolidinedione (TZD) insulin sensitizers have the potential to effectively treat a number of human diseases, however the currently available agents have dose-limiting side effects that are mediated via activation of the transcription factor PPARγ. We have recently shown PPARγ-independent actions of TZD insulin sensitizers, but the molecular target of these molecules remained to be identified. Here we use a photo-catalyzable drug analog probe and mass spectrometry-based proteomics to identify a previously uncharacterized mitochondrial complex that specifically recognizes TZDs. These studies identify two well-conserved proteins previously known as brain protein 44 (BRP44) and BRP44 Like (BRP44L), which recently have been renamed Mpc2 and Mpc1 to signify their function as a mitochondrial pyruvate carrier complex. Knockdown of Mpc1 or Mpc2 in Drosophila melanogaster or pre-incubation with UK5099, an inhibitor of pyruvate transport, blocks the crosslinking of mitochondrial membranes by the TZD probe. Knockdown of these proteins in Drosophila also led to increased hemolymph glucose and blocked drug action. In isolated brown adipose tissue (BAT) cells, MSDC-0602, a PPARγ-sparing TZD, altered the incorporation of 13C-labeled carbon from glucose into acetyl CoA. These results identify Mpc1 and Mpc2 as components of the mitochondrial target of TZDs (mTOT) and suggest that understanding the modulation of this complex, which appears to regulate pyruvate entry into the mitochondria, may provide a viable target for insulin sensitizing pharmacology.
References
[1]
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–1053.
[2]
DeFronzo RA, Abdul-Ghani M (2011) Type 2 Diabetes can be prevented with early pharmacological intervention. Diabetes Care 34: S202–S209.
[3]
Ryder REJ (2011) Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes. The British Journal of Diabetes & Vascular Disease 11: 113–120.
[4]
Colca JR, Kletzien RF (2006) What has prevented the expansion of insulin sensitisers? Expert Opin. Investig. Drugs 15: 205–210.
[5]
Kahn BB, McGraw TE (2010) Rosiglitazone, PPARγ, and type 2 diabetes. N Engl J Med 363: 2667–2669.
[6]
Chen Z, Vigueira PA, Chambers KT, Hall AM, Mitra MS, et al. (2012) Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ –sparing thiazolidinedione. J Biol Chem 287: 23537–23548.
[7]
Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, et al. (2013) Clinical proof of concept with MSDC-0160, a prototype mTOT modulating insulin sensitizer,. Clinical Pharmacology and Therapeutics 93: 352–359.
[8]
Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, et al. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol 70: 77–88.
[9]
Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, et al. (2004) Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286: E252–E260.
[10]
Colca JR, Harrigan GG (2004) Photo-Affinity labeling strategies in identifying the protein ligands of small molecules: Examples of targeted synthesis of drug analog photoprobes. Combinatorial Chemistry and High Throughput Screening 7: 699–704.
[11]
Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, et al. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337: 96–100.
[12]
Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, et al. (2012) Identification and functional expression of the mitochondrial pyruvate carrier. Science 337: 93–96.
[13]
Benga G, Hodarnau A, Tilinca R, Porutiu D, Dancea S, et al. (1979) Fractionation of Human Liver Mitochondria: Enzymic and Morphological Characterization of the Inner and Outer Membranes as Compared to Rat Liver Mitochondria. J Cell Sci 35: 417–429.
[14]
Wiley SE, Murphy AN, Ross SA, van der Geer P, Dixon JE (2007) MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci USA 104: 5318–5323.
[15]
Musselman LP, Fink JL, Narzinski K, Ramachandran PV, Hathiramani SS, et al. (2011) A high-sugar diet produces obesity and insulin resistance in wild-type Drosophila. Dis Model Mech 4(6): 842–849.
[16]
Petrovic N, Shabalina IG, Timmons JA, Cannon B, Nedergaard J (2008) Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPARγ agonist. Am J Physiol Endocrinol Metab 295: E287–E296.
[17]
Loren MA, Burant CF, Kennedy RT (2011) Reducing time and increasing sensitivity in sample preparation for adherent mammalian cell metabolomics. Anal Chem 8: 3406–14.
[18]
Foellmi-Adams LA, Wyse BM, Herron D, Nedergaard J, Kletzien RF (1996) Induction of uncoupling protein in brown adipose tissue. Synergy between norepinephrine and pioglitazone, an insulin-sensitizing agent. Biochem Pharmacol 52: 693–701.
[19]
Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466(7305): 451–456.
[20]
Newgard CB (2012) Interplay between Lipids and Branched-Chain Amino Acids in Development of insulin resistance. Cell Metabolism 14: 606–614.
[21]
Brun RP, Spiegelman BM (1997) PPAR gamma and the molecular control of adipogenesis. J Endocrinol 155: 217–218.
[22]
Sauermann M, Hahne F, Schmidt C, Majety M, Rosenfelder H, et al. (2007) High-throughput flow cytometry–based assay to identify apoptosis-inducing proteins. J Biomol Screen 12: 510–520.
[23]
Wiley SE, Paddock ML, Abresch EC, Gross L, van der Geer P, et al. (2007) The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster. J Biol Chem 282: 23745–23749.
[24]
Paddock MA, Wiley S, Axelrod HL, Cohen AE, Roy M, et al. (2007) MitoNEET is a uniquely folded 2Fe–2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci USA 104: 14342–14347.
[25]
Zuris JA, Ali SS, Yeh H, Nguyen TA, Nechushtai R, et al. (2012) NADPH inhibits [2Fe-2S] cluster protein transfer from diabetes drug target MitoNEET to an Apo-acceptor protein. J Biol Chem 287: 11649–11655.
[26]
Kusminski CM, Holland WL, Sun K, Park J, Spurgin SB, et al. (2012) MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med September 9.
[27]
Satapati S, Sunny NE, Kucejova B, Fu X, He TT, et al. (2012) Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J Lipid Res 53: 1080–1092.
[28]
Sunny NE, Parks EJ, Browning JD, Burgess SC (2011) Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab 14: 804–810.
[29]
Halestrap AP (2012) The mitochondrial pyruvate carrier: has it been unearthed at last? Cell Metab 16: 141–143.
[30]
Divakaruni AS, Wiley SE, Rogers GW, Andreyev AY, Petrosyan , et al. (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 110(14): 5422–5427.
